21, 2025, the FDA announced that the semaglutide shortage was over and that compounding pharmacies need to stop making and selling semaglutide injection products that are copies of FDA-approved products (Ozempic, Wegovy, and Rybelsus)
Both medications can cause side effects such as diarrhea, constipation, dizziness, and headache
Available both in-office and via telemedicine - book now or call to learn more
Alzheimer's & the Nun Study (00:52:34) Exercise & Hippocampal Volume, Falls & Balance (00:57:14) SuperAgers & Athletes
Tirzepatide demonstrates greater weight loss and glycemic control than semaglutide in clinical trials, achieving up to 20.9% body weight reduction versus 14.9-16.0% with semaglutide
Wegovys effect on the body classifies it as a GLP-1 receptor agonist, alongside other treatments like Mounjaro and Nevolat